RCM
PDSB icon

Raleigh Capital Management’s PDS Biotechnology PDSB Stock Holding History

Raleigh Capital Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-46
Closed -$607 – 886
2022
Q4 		$607 Buy
+46
New +$325 ﹤0.01% 729

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
EWA
EP Wealth Advisors Torrance, California $20.3B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raleigh Capital Management's PDSB Position: Q1 2023 in Review

Raleigh Capital Management sold out of PDS Biotechnology (PDSB) in Q1 2023, closing a stake of 46 shares — an estimated $607 sold.

Raleigh Capital Management first reported a position in PDSB in Q4 2022 and held it in 1 quarter. The position peaked at $607 in Q4 2022. 68 funds tracked by Wall St. Rank hold PDSB as of Q1 2023.

  • Raleigh Capital Management reported no remaining PDS Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Raleigh Capital Management sold 46 PDS Biotechnology shares in Q1 2023, an estimated $607.
  • Raleigh Capital Management first reported a position in PDS Biotechnology in Q4 2022 and held it in 1 quarter.
  • Raleigh Capital Management's PDS Biotechnology position peaked at $607 in Q4 2022.
  • 68 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2023.

Based on Raleigh Capital Management's 13F filing for Q1 2023, filed 22 May 2023.